CoChat
Sign Up
Cited by 13Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population

Open access
Iqbal, Sajid, Sabbour, Hani Mohamed, Ashraf, Tanveer, Santos, Raul D., Buckley, Adam·2024·Clinical Therapeutics
DOI 10.1016/j.clinthera.2023.12.003
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE: Inclisiran is the first small interfering RNA-based treatment approved for reducing pro-atherogenic lipoproteins in patients with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol (LDL-C). We report the first evaluation of the effects of inclisiran in a Middle East population. METHODS: We conducted a retrospective review of patients initiating inclisiran treatment at an outpatient diabetology, endocrinology, and cardiology center between May 2021 and December 2022. All patients followed up for 90 days or more, or with at least 1 lipid determination post initiation were included. Participants were categorized into primary prevention (n = 57) and secondary prevention (n = 89) groups according to previous atherosclerotic cardiovascular disease. FINDINGS: Inclisiran was initiated in 146 patients; mean (SD) age was 54.8 (12.12) years, 82 patients (56.2%) were male, 28 patients (19.2%) had received a diagnosis of familial hypercholesterolemia, 89 patients (61%) had received a diagnosis of diabetes mellitus, and 35 patients (23.9%) had a statin intolerance. Median (interquartile range) follow-up was 137 (90 to 193) days. At 90 days, median (interquartile range) reductions in serum LDL-C and triglycerides were -37.9% (-9.5% to -51.2%) and -12.0% (-9.8% to -40.5%), respectively, in primary prevention and -54.1% (-17.1% to -71.4%) and -15.3% (-14% to -38.8%), respectively, in secondary prevention (all, P < 0.001). LDL-C goals were attained in 110 patients (75.3%). Nonattainment of LDL-C goal was attributed to system effect in 26 patients (72.2%), biological effect in 5 patients (13.9%), and discontinuation of treatment in 5 patients (13.9%). Therapy was well tolerated. IMPLICATIONS: This study is the first from the Middle East and North Africa region that reported the real-world efficacy and safety profile of inclisiran in a mixed-risk population of patients with heterozygous familial hypercholesterolemia and other non-familial hypercholesterolemia indications. Clinically meaningful and sustained reductions in pro-atherogenic lipids with good tolerability were observed after inclisiran initiation. Fewer AEs were reported in this predominantly Arabic population, consistent with previous safety reports for inclisiran. It is important to note that no patient stopped inclisiran treatment due to AEs. Strengths of our study included an optimal cohort, patient heterogeneity, and high retention. In addition, we were able to report mean robust effects of inclisiran and good medication tolerability, quite like randomized studies and open-label extension periods. Despite this, our study had some limitations, including selection bias due to the retrospective design and the absence of a comparative group.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2023.12.003

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nearly all studies (n = 85) evaluated medication adherence to moAb PCSK9 inhibitors, while 7 studies evaluated siRNA PCSK9 inhibitor, of which 2 were included in meta-analysis.

    “Nearly all studies (n = 85) evaluated medication adherence to moAb PCSK9 inhibitors, while 7 studies evaluated siRNA PCSK9 inhibitor, of which 2 were included in meta-analysis.15,70”

    From Adherence to PCSK9 Inhibitors in Clinical Practice (2026) · cites this paper as [70]

    The Introduction identifies inclisiran as an siRNA PCSK9 inhibitor, but the paper reports a retrospective patient study, not a count of medication-adherence studies. Searches for the 85- and 7-study counts and the two studies included in a meta-analysis found no passage addressing those figures; the Discussion instead says longer follow-up is needed to assess adherence. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross- Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Pri- mary Care: the DA VINCI study. Eur J Prev Cardiol . 2021;28:1279-1289 .

Cited by

Sorted by citations

Related

Authors
Iqbal, S., Sabbour, H. M., Ashraf, T., Santos, R. D., & Buckley, A.
Affiliations
  • Imperial College London Diabetes Centre (AE)
  • Universidade de São Paulo (BR)
Corresponding author
Iqbal, Sajid
ORCID
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2024-03
Volume
46
Issue
3
Pages
186-193
ISSN
0149-2918 (ISSN-L)
DOI
10.1016/j.clinthera.2023.12.003
OpenAlex
W4390889283
Cited by
13
References
36
Citations by year
2026: 5 · 2025: 4 · 2024: 4
FWCI
5.49
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Therapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
Imperial College London Diabetes Centre
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
inclisiran, hypercholesterolemia, LDL cholesterol lowering, siRNA, familial hypercholesterolemia, atherosclerotic cardiovascular disease, primary prevention, secondary prevention, triglycerides, statin intolerance, diabetes mellitus, LDL-C goal attainment, treatment discontinuation, Middle Eastern populations, real-world outcomes, drug safety and tolerability, lipid-lowering therapy
MeSH terms
Proprotein Convertase 9, Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Female, Humans, Hypercholesterolemia, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Retrospective Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review